Shenguan Holdings (SEHK:829) Stock Looks Cheap But Losses Keep Deepening

Shenguan Holdings came into this earnings season with a beaten up share price and a bargain label, trading around HK$0.25 while analysts see much higher value. The latest H1 2026 report undercuts that bargain story. Revenue sits at ¥455.957 million yet the business still posted a net loss of ¥44.863 million and basic earnings per share stayed in the red.

For a stock priced on hope of a turnaround, another period of loss making operations keeps the spotlight firmly on profitability pressure rather than recovery potential.

Is Shenguan Holdings a genuine bargain at HK$0.25, or just a stock with deepening losses and a cheap price tag for a reason? Compare the current share price against analyst fair value in the valuation analysis for Shenguan Holdings (Group)

H1 2026 Earnings Summary

• Revenue (H1 2026 vs H1 2025): ¥455.957 million vs. ¥443.914 million (modest top line increase year on year)
• Net Loss (H1 2026 vs H1 2025): loss of ¥44.863 million vs. loss of ¥40.586 million (losses widened over the year)
• Basic EPS (H1 2026 vs H1 2025): loss of ¥0.013887 per share vs. loss of ¥0.012563 per share (per share loss deepened)
• Trailing 12-Month Net Loss (to H1 2026 vs to H1 2025): loss of ¥74.05 million vs. loss of ¥22.153 million (TTM net loss, where TTM means trailing twelve months, expanded materially)

Tired of scrolling through dense tables and raw figures just to understand what Shenguan Holdings is really doing financially? See the full visual breakdown of Shenguan Holdings, including how its valuation and fundamentals compare, in one simple dashboard in the company report for Shenguan Holdings (Group).

Shenguan bullish story meets mixed signals

For anyone leaning toward a collagen growth story at Shenguan, the latest half year is a tough fit. Revenue of ¥455.957 million only edges ahead of the prior ¥443.914 million, so the top line does not scream acceleration across food, pharma or skincare. The more encouraging read is that sales are at least holding rather than shrinking while the company pushes across several collagen niches. For a long term platform idea, that stability offers a base, but it does not yet show the higher value health and beauty products changing the earnings profile.

Loss trajectory keeps the bearish case alive

The bear case finds more support in the profit line. Net loss widened to ¥44.863 million in H1 2026 from ¥40.586 million and the trailing 12 month deficit rose to ¥74.05 million from ¥22.153 million. Basic EPS loss also deepened. That pattern points to pressure on Shenguan Holdings as it tries to fund broader collagen ambitions. Recent share price gains over 30 and 90 days suggest traders are willing to speculate on a turn, but the reported numbers still frame this as a loss making, higher risk situation.

After earnings this weak, the real question is whether Shenguan Holdings is facing a temporary setback or a structural earnings problem. Review our risk analysis for Shenguan Holdings (Group) which shows 1 important warning sign

Take Charge Of Your Next Move

If Shenguan Holdings earnings leave you unsure about timing an entry, register for free with Simply Wall St and add it to your Watchlist so you can track price versus fair value and wait for conditions that suit your plan. When you do decide to buy or sell, manage your positions through the Portfolio Command Center which highlights only the most important events affecting your holdings. For a broader view on what others are seeing in Shenguan Holdings and similar opportunities, tap into shared insight and discussion in the Community. By spotting potential catalysts and risks early, you give yourself the opportunity to stay ahead of the wider market.

Seeking Alternatives Beyond Shenguan Holdings?

Fresh ideas can move first when momentum starts building and potential breakouts are still under the radar. Scan these curated stock lists before the crowd and act now.

• Hunt for resilient compounders that aim to hold up when others wobble by scanning the 227 resilient stocks with low risk scores while the market is still looking the other way.
• Target companies backing the AI build out, where demand for chips, power and data capacity is shaping fresh momentum, by reviewing the 89 AI infrastructure stocks ahead of latecomers.
• Ride the shift toward next generation energy by checking the curated 19 nuclear energy infrastructure stocks while these infrastructure plays are still priced as niche ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com